Treatment for breast cancer varies, based on both the patient’s circumstances and type of cancer. The development of treatments to suppress or even eliminate cancer has led to a high survival rate in wealthy countries, with around 85% of patients in the United States and United Kingdom surviving for at least five years from diagnosis. Cancer is a difficult disease to defeat, and survival can depend upon the ability of scientists to counter a specific genetic defect in a specific set of cells.
Imagined in the 1970s and first carried out in the 1980s, gene therapy is one of the newest frontiers in medicine. A number of companies have emerged with the aim of applying gene therapy to specific diseases. For example, Genprex Inc. (GNPX) specializes in tackling non-small cell lung cancer through its developmental drug Oncoprex(TM).
More times than not I've been able to identify a strong move coming within the stock. This was posted over on Real Money Pro, a great place for those folks seeking additional trade ideas! The trade in this scenario was selling covered calls against HALF the long stock.
Genprex adds three new members to its Board of Directors.
Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases. Genprex's technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and other serious diseases who currently have limited treatment options.
AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...
Genprex issues a letter to shareholders, providing corporate and clinical updates.
Benzinga Pro's Stocks To Watch For Wednesday Bellerophon (BLPH) - Following a nearly 170% rally to close Tuesday's session, Bellerophon shares pulled back about 5% to under the $9 level Wednesday morning. ...
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. Advances in biotechnology look to deliver promising new treatment options against breast cancer. Breast cancer is one of the most widely prevalent cancers in the world.
Genprex's newly licensed gene therapy for diabetes explained by lead researcher in new video.
Genprex adds two accomplished life science leaders to its executive team.
Genprex hires new Vice President of Global Clinical Operations.
While adding money to the balance sheet is seldom a negative, the impact it can have on shareholders or the stock price can absolutely create a negative overhang sometimes lasting for months, if not longer. It's easy to find examples of a "bad" capital raise as well as a good capital raise, but it is seldom you see both from the same company within a two month span, but that's exactly what we got with Genprex .
Genprex Signs Exclusive Worldwide License Agreement with MD Anderson Cancer Center
If you want a perfect example of this, look at two recent capital raises: one from Tesla and one from Genprex over the past week.